BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31031206)

  • 21. A novel core fucose-specific lectin from the mushroom Pholiota squarrosa.
    Kobayashi Y; Tateno H; Dohra H; Moriwaki K; Miyoshi E; Hirabayashi J; Kawagishi H
    J Biol Chem; 2012 Oct; 287(41):33973-82. PubMed ID: 22872641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease.
    Ritts RE; Nagorney DM; Jacobsen DJ; Talbot RW; Zurawski VR
    Pancreas; 1994 Nov; 9(6):707-16. PubMed ID: 7846013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
    Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
    EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer.
    Kaur S; Chakraborty S; Baine MJ; Mallya K; Smith LM; Sasson A; Brand R; Guha S; Jain M; Wittel U; Singh SK; Batra SK
    PLoS One; 2013; 8(2):e55171. PubMed ID: 23383312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures.
    Miyoshi E; Nakano M
    Proteomics; 2008 Aug; 8(16):3257-62. PubMed ID: 18646007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
    Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis for specific recognition of core fucosylation in N-glycans by Pholiota squarrosa lectin (PhoSL).
    Yamasaki K; Kubota T; Yamasaki T; Nagashima I; Shimizu H; Terada RI; Nishigami H; Kang J; Tateno M; Tateno H
    Glycobiology; 2019 Jul; 29(7):576-587. PubMed ID: 30913288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection.
    Fahrmann JF; Schmidt CM; Mao X; Irajizad E; Loftus M; Zhang J; Patel N; Vykoukal J; Dennison JB; Long JP; Do KA; Zhang J; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger J; Yip-Schneider MT; Maitra A; Wolpin BM; Hanash S
    Gastroenterology; 2021 Mar; 160(4):1373-1383.e6. PubMed ID: 33333055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
    Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.
    Reitz D; Gerger A; Seidel J; Kornprat P; Samonigg H; Stotz M; Szkandera J; Pichler M
    J Clin Pathol; 2015 Jun; 68(6):427-33. PubMed ID: 25759406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum APRIL, a potential tumor marker in pancreatic cancer.
    Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
    Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
    Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
    Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic Cancer Insights: Optimization of the Diagnostic Capacity of Tumor Biomarkers.
    Delgado JA; Ballesteros MA; Parera MM; Bauça JM
    Lab Med; 2021 Nov; 52(6):550-557. PubMed ID: 33900408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.